Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 31, 2024 18:54 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

THE WOODLANDS, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the outcome of the U.S. Food and Drug Administration (FDA) Endocrinologic and...
October 23, 2024 09:00 ET | Source: Lexicon Pharmaceuticals, Inc.

New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024

THE WOODLANDS, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new analysis of its Phase 3 SCORED clinical trial demonstrating the protective...
October 22, 2024 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

Top-line Data Now Anticipated in Q1 2025 LX9211 has previously received Fast Track designation from the U.S. Food and Drug Administration (FDA) for DPNP THE WOODLANDS, Texas, Oct. 22, 2024 ...
October 16, 2024 16:35 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe

THE WOODLANDS, Texas, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Viatris Inc. (Nasdaq: VTRS) has obtained an exclusive license from Lexicon...
September 27, 2024 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress

Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon’s novel dual SGLT1 and SGLT2 inhibitor in this underserved and growing patient population Study design intended to...
September 16, 2024 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer

THE WOODLANDS, Texas, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeff Wade, president and chief operating officer, has decided to step down...
September 10, 2024 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes

Study results aligned with positive clinical trial outcomes for type 1 diabetes treatment with sotagliflozin TIR measures approach target set by American Diabetes Association Data to be presented...
September 03, 2024 16:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences

THE WOODLANDS, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lexicon management will participate in the following investor conferences...
September 03, 2024 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA® (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration

Results showed reductions in heart attack, stroke and heart failure events in all patients with even greater benefit for heart failure events among patients with longer diabetes duration New analysis...
August 21, 2024 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista

Advisory Committee Meeting Scheduled for October 31, 2024; PDUFA Goal Date Remains December 20, 2024 Lexicon Seeks Approval for ZYNQUISTA™ (sotagliflozin) as an Adjunct to Insulin Therapy for...